Tumor cell-intrinsic PD-1 regulates chemotherapy resistance in colorectal cancer cells by activating downstream MAPK signaling
8.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-20 00:04
摘要：
The research investigates the role of tumor cell-intrinsic PD-1 (ciPD-1) in colorectal cancer (CRC), revealing that high ciPD-1 levels correlate with chemotherapy resistance and poor patient outcomes. The study demonstrates that ciPD-1 activates MAPK signaling pathways, enhancing cell survival under chemotherapy stress. Inhibiting ciPD-1 increases sensitivity to chemotherapy, suggesting that targeting ciPD-1 could improve treatment efficacy in CRC patients. This highlights the potential for innovative therapeutic strategies combining PD-1 inhibitors with conventional chemotherapy.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0
business_impact
0.5分+0.5
scientific_rigor
1.5分+1.5
timeliness_innovation
1.5分+1.5
investment_perspective
2.5分+2.5
market_value_relevance
1.0分+1.0
team_institution_background
0.5分+0.5
technical_barrier_competition
1.0分+1.0
关键证据
High expression levels of ciPD-1 in CRC tumors are associated with inferior outcomes.
Inhibition of ciPD-1 sensitizes CRC cells to chemotherapy.
ciPD-1 signaling occurs via MAPK signaling in CRC cells.
真实性检查
否
AI评分总结
The research investigates the role of tumor cell-intrinsic PD-1 (ciPD-1) in colorectal cancer (CRC), revealing that high ciPD-1 levels correlate with chemotherapy resistance and poor patient outcomes. The study demonstrates that ciPD-1 activates MAPK signaling pathways, enhancing cell survival under chemotherapy stress. Inhibiting ciPD-1 increases sensitivity to chemotherapy, suggesting that targeting ciPD-1 could improve treatment efficacy in CRC patients. This highlights the potential for innovative therapeutic strategies combining PD-1 inhibitors with conventional chemotherapy.